- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Cadila Launches Second Biosimilar in a Week
On the heels of its earlier announcement of a bevacizumab biosimilar launch, India-based Cadila Pharmaceuticals said it also has a rituximab biosimilar entering the marketplace.
Cadila Pharmaceuticals said it has launched a biosimilar rituximab (Ritucad) for the Indian market. The drug is used for the treatment of blood cancer and rheumatoid arthritis. Rituximab is used in the treatment of non-Hodgkin lymphoma. Each year there are more than 28,000 new cases of lymphoma in India, the company said.
This was the company’s second biosimilar launch announcement in a week. Cadila previously stated that the bevacizumab biosimilar Bevaro would be made available in India for the treatment of ovarian cancer, glioblastoma multiforme, colorectal cancer, breast cancer, lung cancer, cervical cancer, and kidney cancer.
Cadila is based in Ahmedabad, India. The company stated in the bevacizumab launch announcement that it intends to continue launching biosimilar products this year.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
CHMP Pushes 3 Biosimilars Forward, Spelling Hope for Ophthalmology, Supportive Care Markets
February 6th 2025The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended 3 biosimilars and new indications for reference biologics, moving them closer to final European approval and expanding patient access.
The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars
February 5th 2025Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast majority of biologics have no pipeline, which limits savings potential for the health care system.
